Clinical Trial Update: A 10-Week Study Evaluating the Efficacy And Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder [Phase 3]

View source ↗

Summary

A 10-week Phase 3 trial evaluating the efficacy and safety of PD 0332334 for Generalized Anxiety Disorder has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Generalized Anxiety Disorder

Drugs mentioned

• PD 0332334

Snippet

Sponsor: Pfizer | Conditions: Generalized Anxiety Disorder | Phase 3 | Status: COMPLETED